Literature DB >> 2935581

Association of symptomatic human infection with Toxoplasma gondii with imbalance of monocytes and antigen-specific T cell subsets.

I Sklenar, T C Jones, S Alkan, P Erb.   

Abstract

During recent symptomatic toxoplasmosis, alterations in quantity and function of mononuclear cells in peripheral blood were observed. Flow cytofluorometric analysis and differential leukocyte counts revealed increased absolute numbers of T8+ cells, Leu 7+ (natural killer/killer) cells, and monocytes. T4+ cells and HLA-DR+ cells were not significantly changed. T4/T8 cell ratios were reversed in symptomatic toxoplasmosis (0.7 +/- 0.3) and normal in chronic infection (1.7 +/- 0.5). Toxoplasma antigen induced higher numbers of T8+ and TQ1+ cells in four T cell lines from two individuals with symptomatic infection than in five T cell lines from three individuals with asymptomatic infection. Eight cloned T cell lines produced gamma interferon in an antigen-specific fashion and in higher amounts when they originated from an asymptomatic subject than from a symptomatic subject. These results indicate that marked alterations in properties of immunoregulatory cells are characteristic of recent symptomatic toxoplasmosis. The transient immune dysfunction may be a major part of the observed disease and/or a feature of successful parasitism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2935581     DOI: 10.1093/infdis/153.2.315

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Subversion of innate and adaptive immune responses by Toxoplasma gondii.

Authors:  Christine Lang; Uwe Gross; Carsten G K Lüder
Journal:  Parasitol Res       Date:  2006-10-06       Impact factor: 2.289

2.  Down-regulation of MHC class II molecules and inability to up-regulate class I molecules in murine macrophages after infection with Toxoplasma gondii.

Authors:  C G Lüder; T Lang; B Beuerle; U Gross
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

3.  Human T-cell clones against Toxoplasma gondii: production of interferon-gamma, interleukin-2, and strain cross-reactivity.

Authors:  R Saavedra; P Hérion
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

4.  Use of acute-stage-specific antigens of Toxoplasma gondii for serodiagnosis of acute toxoplasmosis.

Authors:  Y Suzuki; P Thulliez; J S Remington
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

5.  A switch towards Th2 during serological rebound in children with congenital toxoplasmosis.

Authors:  S Kahi; G J Cozon; J M Pinon; T Greenland; M Wallon; M Al Kurdi; J Ferrandiz; F Peyron
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

6.  CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice.

Authors:  S J Parker; C W Roberts; J Alexander
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

7.  Mucosal and systemic cellular immune responses induced by Toxoplasma gondii antigens in cyst orally infected mice.

Authors:  T Chardès; F Velge-Roussel; P Mevelec; M N Mevelec; D Buzoni-Gatel; D Bout
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

Review 8.  Role of gamma interferon in Toxoplasma gondii infection.

Authors:  C S Subauste; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

9.  Induction of antigen-specific human cytotoxic T cells by Toxoplasma gondii.

Authors:  I A Khan; K A Smith; L H Kasper
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

10.  Experimental Porcine Toxoplasma gondii Infection as a Representative Model for Human Toxoplasmosis.

Authors:  Julia Nau; Silvia Kathrin Eller; Johannes Wenning; Katrin Henrike Spekker-Bosker; Horst Schroten; Christian Schwerk; Andrea Hotop; Uwe Groß; Walter Däubener
Journal:  Mediators Inflamm       Date:  2017-08-13       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.